187 related articles for article (PubMed ID: 31107743)
21. Prospective evaluation of
Jambor I; Kuisma A; Kähkönen E; Kemppainen J; Merisaari H; Eskola O; Teuho J; Perez IM; Pesola M; Aronen HJ; Boström PJ; Taimen P; Minn H
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):355-364. PubMed ID: 29147764
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
[TBL] [Abstract][Full Text] [Related]
23. A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.
Ideguchi M; Nishizaki T; Ikeda N; Okamura T; Tanaka Y; Fujii N; Ohno M; Shimabukuro T; Kimura T; Ikeda E; Suga K
J Neurooncol; 2018 Jul; 138(3):537-548. PubMed ID: 29516344
[TBL] [Abstract][Full Text] [Related]
24. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
[TBL] [Abstract][Full Text] [Related]
25. 11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas.
D'Souza MM; Sharma R; Jaimini A; Panwar P; Saw S; Kaur P; Mondal A; Mishra A; Tripathi RP
Clin Nucl Med; 2014 Sep; 39(9):791-8. PubMed ID: 25036022
[TBL] [Abstract][Full Text] [Related]
26. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI.
Cicone F; Filss CP; Minniti G; Rossi-Espagnet C; Papa A; Scaringi C; Galldiks N; Bozzao A; Shah NJ; Scopinaro F; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):905-15. PubMed ID: 25750084
[TBL] [Abstract][Full Text] [Related]
27. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
28. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
29. Comparison of O-(2-
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
[TBL] [Abstract][Full Text] [Related]
30. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
31. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic Performance and Safety of Positron Emission Tomography Using
Wakabayashi T; Iuchi T; Tsuyuguchi N; Nishikawa R; Arakawa Y; Sasayama T; Miyake K; Nariai T; Narita Y; Hashimoto N; Okuda O; Matsuda H; Kubota K; Ito K; Nakazato Y; Kubomura K
Asia Ocean J Nucl Med Biol; 2017; 5(1):10-21. PubMed ID: 28840134
[TBL] [Abstract][Full Text] [Related]
33. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
34. Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.
Vettermann FJ; Felsberg J; Reifenberger G; Hasselblatt M; Forbrig R; Berding G; la Fougère C; Galldiks N; Schittenhelm J; Weis J; Albert NL; Schüller U
Clin Nucl Med; 2018 Dec; 43(12):895-898. PubMed ID: 30358620
[TBL] [Abstract][Full Text] [Related]
35. [Value of 18F-FDG PET imaging in diagnosing tumor residue of intracranial glioma after surgery and radiotherapy].
Chen YR; Li WX; Lin YR; Chen LH
Ai Zheng; 2004 Oct; 23(10):1210-2. PubMed ID: 15473938
[TBL] [Abstract][Full Text] [Related]
36. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
[TBL] [Abstract][Full Text] [Related]
37. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
38. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
39. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
